Post by
modulex on Jan 03, 2016 11:35am
DIAGNOCURE-HOLOGIC
to all of you shareholders do not sign any consent to the proposed transaction if you receive paperwork in the mail or otherwise. the transaction must and will be improved for a return of at least $0.25 to shareholders, rest assured. the amount of CAD $5.5 million is based on what financial basis? Diagnocre has not to grant a right of first refusal right to Hologic about its PCP asset. Both PCP and GCC have nothing to do with Hologic. If Hologic shows an interest for PCP it should just as well do so regarding GCC and consider buying Diagnocure outright. There is also the fact to consider that Diagnocure will likely not be receiving any royalties from Hologic if this deal goes through. Hologic will then endeavour to maximize the PCA3 asset with its scientific team and who knows sell the asset someday at a high premium, without any financial benefit to Diagnocure. The proposed transaction must take into account a "goodwill" criteria to demonstrate that this transaction is not resulting in a fire-sale, otherwise it makes no sense.